mAbs can have several mechanisms of action, including initiation of ADCC, mediated by engagement of the CD16 (FcγRIII) activating receptor on the NK cell with the Fc portion of the antibody that is directed toward the tumor ligand (174). This evidence concerns the gene FCGR3A and neoplasm.